Skip to main content

Table 4 Within- and between-group comparisons of the changes from baseline to endpoint measures for blood pressure and lipid profile in the saffron and placebo groups of asthmatic patients

From: An evaluation of the effects of saffron supplementation on the asthma clinical symptoms and asthma severity in patients with mild and moderate persistent allergic asthma: a double-blind, randomized placebo-controlled trial

Variables Saffron (N = 38) Placebo(N = 38) P-value*
Value P-value¥ Value P-value¥
Systolic pressure (mm Hg)
 Baseline 11.00 (11.00–12.00)   11.00 (11.00–12.00)   
 8 weeks (endpoint) 11 (10.75–12.00)   11.75 (11.00–12.00)   
 Changes −0.11 ± 0.39 0.08 0.02 ± 0.11 0.70 0.03
Diastolic pressure (mm Hg)
 Baseline 8.00 (7.00–8.00)   8.00 (7.00–8.00)   
 8 weeks (endpoint) 7.25 (7.00–8.00)   8.00 (7.50–8.00)   
 Changes −0.02 ± 0.44 0.15 0.15 ± 0.30 0.005 0.04
Total cholesterol
 Baseline 196.82 ± 42.11   192.74 ± 28.93   
 8 weeks (endpoint) 162.52 ± 36.95   173.47 ± 39.87   0.08
 Changes −34.28 ± 32.23 < 0.001 −19.26 ± 42.04 0.008  
Triglyceride
 Baseline 159.83 ± 41.20   149.30 ± 48.27   
 8 weeks (endpoint) 139.48 ± 34.39   153.18 ± 44.99   0.002
 Changes −20.34 ± 30.28 < 0.001 3.88 ± 34.94 0.49  
LDL-C
 Baseline 118.54 ± 36.03   120.74 ± 27.35   
 8 weeks (endpoint) 80.09 ± 35.85   121.82 ± 35.16   < 0.001
 Changes −38.44 ± 41.82 < 0.001 1.08 ± 25.76 0.79  
HDL-C
 Baseline 45.32 ± 13.46   45.57 ± 13.01   
 8 weeks (endpoint) 48.34 ± 15.49   47.35 ± 10.62   0.68
 Changes 3.02 ± 15.53 0.23 1.78 ± 10.51 0.30  
  1. LDL-C low density lipoprotein, HDL-C high density lipoprotein *p-value for comparing the changes of variables between the groups. Mann whitney test was used for systolic and diastolic blood pressure and independent sample T test for lipid profile. ¥p-value for comparing baseline, with endpoint values within each group. Paired samples t-test was used. Values are expressed as mean ± SD for parametric data and median (25th, 75th percentiles) for non-parametric data